¼¼°èÀÇ ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå
Diabetes Monitoring Devices
»óǰÄÚµå : 1744693
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,130,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,390,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 175¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 121¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 175¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÚ°¡Ç÷´çÃøÁ¤ Àåºñ´Â CAGR 5.2%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 110¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ µð¹ÙÀ̽º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 8.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 33¾ï ´Þ·¯, Áß±¹Àº CAGR 9.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº 2024³â¿¡ 33¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 9.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 36¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.2%¿Í 6.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë Áúº´ °ü¸®¿¡¼­ ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â°¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â´Â ¼¼°è¿¡¼­ °¡Àå ÈçÇÑ ¸¸¼ºÁúȯ Áß ÇϳªÀÎ ´ç´¢º´ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î, ȯÀÚ¿Í ÀÇ·áÁø¿¡°Ô Ç÷´ç ¼öÄ¡¿¡ ´ëÇÑ ½Ç½Ã°£ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© Ä¡·á °èȹ ¼ö¸³¿¡ ÀÖ¾î ´õ ³ªÀº ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î 5¾ï ¸í ÀÌ»óÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ¾É¾ÆÀÖ´Â »ýȰ½À°ü, ½Ä½À°ü º¯È­, °í·ÉÈ­ µîÀ¸·Î ÀÎÇØ ´ç´¢º´ ȯÀÚ°¡ ºü¸£°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó, Á¤È®Çϰí Á¢±ÙÇϱ⠽¬¿î Áö¼ÓÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ Çʿ伺ÀÌ ±× ¾î´À ¶§º¸´Ù ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±âµéÀº Ç÷´ç Á¶ÀýÀ» À¯ÁöÇÔÀ¸·Î½á ½ÉÇ÷°üÁúȯ, ½Å°æ Àå¾Ö, ½ÅºÎÀü, ½Ã·Â ÀúÇÏ¿Í °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ç÷´ç ÃøÁ¤±â(BGM)¿Í °°Àº ±âÁ¸ Àåºñ´Â Àú·ÅÇÑ °¡°Ý°ú Æí¸®ÇÔÀ¸·Î ¿©ÀüÈ÷ ³Î¸® »ç¿ëµÇ°í ÀÖÁö¸¸, ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ ¹× Ç÷¡½Ã Ç÷´ç ¸ð´ÏÅÍ´Â ¼Õ°¡¶ôÀ» ÂÁö ¾Ê°íµµ ºÐ ´ÜÀ§ÀÇ ÃֽŠÁ¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ºí·çÅõ½º ¹× ¹«¼± ¿¬°áÀÇ ÅëÇÕÀ¸·Î ÀÌ·¯ÇÑ µµ±¸´Â ¾Û°ú µ¿±âÈ­, Ŭ¶ó¿ìµå µ¥ÀÌÅÍ ÀúÀå, ½Ç½Ã°£ ¾Ë¸²À» Á¦°øÇÏ´Â ½º¸¶Æ® ±â±â·Î º¯¸ðÇÏ¿© ȯÀÚ¿¡°Ô ´õ Å« ÀÚÀ²¼ºÀ» ºÎ¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛÀº ÀçÅà ¸¸¼ºÁúȯ °ü¸®¿¡ Á¡Á¡ ´õ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â´Â °³ÀÎ °ü¸®¿Í ´õ ±¤¹üÀ§ÇÑ °øÁߺ¸°Ç ¼º°ú¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

±â¼úÀº ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±âÀÇ ±â´É¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿À°í Àִ°¡?

±â¼ú Çõ½ÅÀº ´ç´¢º´ ¸ð´ÏÅ͸µ ȯ°æÀ» ÀçÆíÇϰí ÀÖÀ¸¸ç, ±â±âÀÇ Á¤È®¼º, »ç¿ë ÆíÀǼº ¹× Àüü µðÁöÅÐ °Ç°­ »ýŰ迡 ´ëÇÑ ÅëÇÕÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Áö¼ÓÇü Ç÷´ç ¸ð´ÏÅÍ(CGM)´Â ÇöÀç ÃÖ´ë 2ÁÖ±îÁö Âø¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ½Ç½Ã°£ ÃßÀû°ú ÀúÇ÷´ç ¶Ç´Â °íÇ÷´çÀÌ ÀÓ¹ÚÇÑ °æ¿ì ¿¹Ãø °æ°í¸¦ ÅëÇØ °æ°íÇÏ´Â ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ¹ÙÀÌ¿À¼¾½Ì ¼ÒÀç¿Í È¿¼Ò ±â¼úÀÇ ¹ßÀüÀ¸·Î ÇǺΠÀڱذú ±³Á¤ Çʿ伺À» ÃÖ¼ÒÈ­Çϸ鼭 ÃøÁ¤°ªÀÇ Á¤È®µµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â´Â Á¡Á¡ ´õ ÀÛ°í, ´«¿¡ ¶çÁö ¾ÊÀ¸¸ç, ºñħ½ÀÀûÀ¸·Î ¹ßÀüÇϰí ÀÖÀ¸¸ç, Àû¿Ü¼± ºÐ±¤¹ý°ú ¹ßÇÑ ºÐ¼®À» ÀÌ¿ëÇÑ ¹Ù´Ã ¾ø´Â Æ÷µµ´ç ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀÔ´Ï´Ù. ½º¸¶Æ®Æù°úÀÇ ÅëÇÕÀ» ÅëÇØ »ç¿ëÀÚ´Â Æ÷µµ´ç ÃøÁ¤°ª°ú ÇÔ²² ½Ä»ç, Åõ¾à, ¿îµ¿À» ±â·ÏÇÒ ¼ö ÀÖÀ¸¸ç, AI ±â¹Ý Ç÷§ÆûÀº ÀÌ·¯ÇÑ º¯¼ö¸¦ ºÐ¼®ÇÏ¿© °³Àκ° ¸ÂÃã ÃßõÀ» Á¦°øÇÕ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº ÀÓ»óÀÇ¿ÍÀÇ µ¥ÀÌÅÍ °øÀ¯¸¦ ¿ëÀÌÇÏ°Ô ÇÏ¿© ¿ø°Ý ¸ð´ÏÅ͸µ, Á¶±â °³ÀÔ, º´¿ø ¹æ¹® Ƚ¼ö °¨¼Ò¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Àΰø ÃéÀå ±â¼úÀ̶ó°íµµ ºÒ¸®´Â Æó¼â ·çÇÁ Àν¶¸° Àü´Þ ½Ã½ºÅÛÀº Àν¶¸° ÆßÇÁ¿Í CGMÀ» °áÇÕÇÏ¿© ½Ç½Ã°£ Æ÷µµ´ç µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î Àν¶¸° Àü´ÞÀ» ÀÚµ¿È­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÆíÀǼº°ú Æí¾ÈÇÔÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, Á¦1Çü ¹× Á¦2Çü ´ç´¢º´ ȯÀÚÀÇ ¿¹Èĸ¦ ȹ±âÀûÀ¸·Î °³¼±Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ÇコÄɾî¿Í ¿þ¾î·¯ºíÀÇ °áÇÕÀ¸·Î ´ç´¢º´ ¸ð´ÏÅ͸µÀº ½º¸¶Æ®ÇÏ°í ¿¹Ãø °¡´ÉÇÑ Ä¿³ØÆ¼µå ÄɾîÀÇ ÆÐ·¯´ÙÀÓÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

¿Ö ȯÀÚ ±ÇÇÑ ºÎ¿©¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏ ÅëÇÕÀÌ ±â±â º¸±ÞÀ» ÃËÁøÇϴ°¡?

ȯÀÚ Áß½ÉÀÇ Ä¡·á¿Í »ýȰ½À°ü ±â¹Ý Áúº´ °ü¸®·ÎÀÇ ÀüȯÀº ÷´Ü ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±âÀÇ Ã¤ÅÃÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Çö´ëÀÇ È¯ÀÚµéÀº ´õ ÀÌ»ó ¼öµ¿ÀûÀÎ Ä¡·áÀÇ ¼öÇýÀÚ°¡ ¾Æ´Ñ, ¸íÈ®ÇÑ ÀλçÀÌÆ®¿Í ½Ç¿ëÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇϸ鼭 ÀÏ»ó »ýȰ¿¡ ¸Å²ô·´°Ô ÅëÇյǴ µµ±¸¸¦ ±â´ëÇÏ´Â ´Éµ¿ÀûÀÎ Âü¿©ÀÚÀÔ´Ï´Ù. ½º¸¶Æ®¿öÄ¡³ª ÇÇÆ®´Ï½º Æ®·¡Ä¿¿Í Åë½ÅÇÏ´Â CGM°ú °°ÀÌ ÀÏ»ó »ýȰ¿¡ ½±°Ô ÅëÇÕÇÒ ¼ö ÀÖ´Â ±â±â´Â ƯÈ÷ ±â¼ú¿¡ Á¤ÅëÇÑ »ç¿ëÀÚ³ª ÀþÀº Ãþ¿¡¼­ Å« È£ÀÀÀ» ¾ò°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ Æ÷µµ´ç µ¥ÀÌÅÍÀÇ ½É¸®Àû ¿µÇâÀº ½Ä´Ü ±ÇÀå »çÇ×, ¿îµ¿ ½À°ü, Åõ¾à ½ºÄÉÁÙÀ» ÁؼöÇϵµ·Ï À¯µµÇÕ´Ï´Ù. ¿îµ¿¼±¼ö, ¹Ù»Û Àü¹®°¡, ´ç´¢º´À» ¾Î°í ÀÖ´Â Àڳฦ µ¹º¸´Â º¸È£ÀÚ¿¡°Ô´Â ¿ø°Ý ¾Ë¸² ¹× Ãß¼¼ ±×·¡ÇÁ¿Í °°Àº ±â´ÉÀÌ ¾È½ÉÇÏ°í »óȲÀ» ´õ Àß °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ÇöÀç ¸¹Àº ±â±âµéÀÌ ´Ù±¹¾î ÀÎÅÍÆäÀ̽º, À½¼º ºñ¼­, ±×¸®°í Áúº´ÀÇ ¸ÞÄ¿´ÏÁò°ú ÀÚ°¡ °ü¸® ¹æ¹ý¿¡ ´ëÇÑ ÀÌÇØ¸¦ µ½´Â ±³À° ±â´ÉÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º¸¦ Á¦´ë·Î ¹ÞÁö ¸øÇÏ´Â »ç¶÷µé¿¡°Ô´Â Á¢±Ù¼º°ú °Ç°­ ÇüÆò¼ºÀ» °³¼±Çϱâ À§ÇØ °£ÆíÇϰí Àú·ÅÇÑ ¸ðµ¨ÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù. ´ç´¢º´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ³«ÀÎÀÌ °¨¼ÒÇÔ¿¡ µû¶ó, ¸ð´ÏÅ͸µ ±â±â´Â ÀÓ»óÀû µµ±¸°¡ ¾Æ´Ñ ÀÏ»óÀûÀÎ À£ºùÀÇ ÆÄÆ®³Ê·Î °£Áֵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÇ º¯È­´Â Ç÷´çÀ» ¼º°øÀûÀ¸·Î Á¶ÀýÇÏ°í ´ç´¢º´°ú °ü·ÃµÈ ÇÕº´ÁõÀÇ Àü¹ÝÀûÀÎ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ä¼ÒÀÎ ´õ ³ôÀº Âü¿©¿Í Àå±âÀûÀÎ Çå½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Àα¸Åë°èÇÐÀû, ±â¼úÀû, Á¤Ã¥Àû, ÇൿÀû ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀÎÀÇ ÃÑü·Î¼­ ´õ ³ªÀº Áúº´ ÃßÀû°ú °³º°È­µÈ Ä¡·á°¡ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ µµ½ÃÈ­, °¡°ø½Äǰ ¼Òºñ, À¯ÀüÀû ¼ÒÀÎÀÌ »õ·Î¿î Áø´ÜÀÇ ±ÞÁõ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ´Â ½ÅÈï±¹¿¡¼­ ´ç´¢º´ÀÇ ¼¼°è À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¼±Áø±¹¿¡¼­´Â °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ ¸¸¼ºÁúȯ °ü¸® µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÀÇ·á °³ÇõÀº Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ º¸Á¶±Ý Áö±Þ, º¸Çè Àû¿ë ¹üÀ§ È®´ë, ´ëÁßÀ» ´ë»óÀ¸·Î ÇÑ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÇ ½ÃÀÛÀ» ÅëÇØ Áö¿øÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ °¡¼ÓÈ­µÈ ¿¹¹æ ÀÇ·á¿Í ¿ø°Ý ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿þ¾î·¯ºí Ç÷´ç ¸ð´ÏÅÍ´Â °¡»ó Ä¡·á Àü·«ÀÇ Á߽ɿ¡ ¼­°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÇÏÀÌÅ×Å© ±â¾÷°ú ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ÆÄÆ®³Ê½ÊÀº ¿þ¾î·¯ºí, EHR, AI ºÐ¼®À» °áÇÕÇÏ¿© Á¾ÇÕÀûÀÎ ´ç´¢º´ °ü¸®¸¦ À§ÇÑ º¸´Ù ÅëÇÕÀûÀÎ »ýŰ踦 ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµ°¡ ¿¬±¸°³¹ß ³ë·ÂÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, Á¦Á¶¾÷üµéÀº µðÀÚÀΰú ±â´É Çõ½ÅÀ» À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷°è ÁÖ¿ä ¾÷üµéÀÇ ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ Áö¿ªÀ¸·ÎÀÇ Àü·«Àû ÁøÃâÀº »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ±â¼úÀÌ ¼º¼÷Çϰí Àü ¼¼°è °Ç°­ ¿ì¼±¼øÀ§°¡ Àû±ØÀûÀÎ Ä¡·á·Î ÀüȯµÊ¿¡ µû¶ó ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â´Â ÀÌ ¸¸¿¬ÇÑ Áúº´À» °ü¸®Çϱâ À§ÇÑ ±âº» µµ±¸°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÀÚ°¡Ç÷´çÃøÁ¤±â, Áö¼Ó Ç÷´çÃøÁ¤±â), ÀûÀÀÁõ(IÇü ´ç´¢º´, IIÇü ´ç´¢º´, ÀӽŠ´ç´¢º´), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø·á¼Ò, ÀçÅÃÀÇ·á ÇöÀå, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 42°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diabetes Monitoring Devices Market to Reach US$17.5 Billion by 2030

The global market for Diabetes Monitoring Devices estimated at US$12.1 Billion in the year 2024, is expected to reach US$17.5 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Self-Monitoring Blood Glucose Devices, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Continuous Glucose Monitoring Devices segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 9.8% CAGR

The Diabetes Monitoring Devices market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Diabetes Monitoring Devices Market - Key Trends & Drivers Summarized

Why Are Diabetes Monitoring Devices Crucial in Modern Disease Management?

Diabetes monitoring devices have become indispensable in the management of one of the world’s most prevalent chronic diseases, offering patients and healthcare providers real-time insights into blood glucose levels and enabling better decision-making in treatment plans. With diabetes affecting over 500 million people globally and projections indicating a rapid rise due to sedentary lifestyles, poor dietary habits, and aging populations, the need for precise, accessible, and continuous glucose monitoring has never been greater. These devices play a pivotal role in preventing complications such as cardiovascular disease, neuropathy, kidney failure, and vision loss by helping maintain glycemic control. Traditional devices like blood glucose meters (BGMs) remain widely used for their affordability and simplicity, but continuous glucose monitoring (CGM) systems and flash glucose monitors are gaining dominance for their ability to provide minute-by-minute updates without the need for finger pricks. The integration of Bluetooth and wireless connectivity has transformed these tools into smart devices that sync with apps, allow for cloud data storage, and offer real-time alerts, empowering patients with greater autonomy. Additionally, healthcare systems are increasingly emphasizing home-based chronic disease management, making diabetes monitoring devices essential to both individual care and broader public health outcomes.

How Is Technology Revolutionizing the Functionality of Diabetes Monitoring Devices?

Technological innovation is reshaping the diabetes monitoring landscape, driving improvements in device accuracy, usability, and integration into holistic digital health ecosystems. Continuous glucose monitors (CGMs) now offer sensor wear times of up to two weeks, with real-time tracking and predictive alerts that warn of impending hypo- or hyperglycemic events. Advances in biosensing materials and enzymatic technology have increased the precision of readings while minimizing skin irritation and calibration needs. Wearable devices are becoming smaller, more discreet, and non-invasive, with research underway for needle-free glucose monitoring using infrared spectroscopy and sweat analysis. Smartphone integration enables users to log meals, medications, and exercise alongside glucose readings, while AI-driven platforms analyze these variables to deliver personalized recommendations. Cloud-based platforms facilitate data sharing with clinicians, allowing for remote monitoring, early intervention, and reduced in-person visits-an advantage magnified during the COVID-19 pandemic. Closed-loop insulin delivery systems, often referred to as artificial pancreas technologies, are combining insulin pumps and CGMs to automate insulin delivery based on real-time glucose data. These innovations are not just enhancing convenience and comfort but are also dramatically improving outcomes for both type 1 and type 2 diabetes patients. As digital health and wearables converge, diabetes monitoring is evolving into a smart, predictive, and connected care paradigm.

Why Is Patient Empowerment and Lifestyle Integration Driving Device Adoption?

The shift toward patient-centered care and lifestyle-based disease management is significantly boosting the adoption of advanced diabetes monitoring devices. Modern patients are no longer passive recipients of care but active participants who expect tools that fit seamlessly into their daily lives while offering clear insights and actionable data. Devices that integrate easily into routine activities-like CGMs that communicate with smartwatches or fitness trackers-are gaining favor, particularly among tech-savvy users and younger demographics. The psychological impact of real-time glucose data also encourages better adherence to dietary recommendations, exercise routines, and medication schedules. For athletes, busy professionals, or caregivers managing children with diabetes, features like remote alerts and trend graphs provide peace of mind and enhanced situational control. Many of these devices now support multilingual interfaces, voice assistants, and educational features that promote understanding of disease mechanics and self-care practices. In underserved populations, simplified and affordable models are being introduced to improve access and health equity. As awareness of diabetes grows and stigma decreases, monitoring devices are increasingly viewed not as clinical tools but as everyday wellness companions. This shift in perception is fostering higher engagement and long-term commitment, critical factors in achieving successful glycemic control and reducing the overall burden of diabetes-related complications.

What Are the Key Drivers Powering Global Growth in the Diabetes Monitoring Devices Market?

The growth in the diabetes monitoring devices market is driven by a confluence of demographic, technological, policy, and behavioral factors that collectively emphasize better disease tracking and personalized care. A major driver is the escalating global prevalence of diabetes, particularly in emerging economies where urbanization, processed food consumption, and genetic predispositions are fueling a surge in new diagnoses. Simultaneously, aging populations in developed nations are contributing to increased demand for chronic disease management tools. Government initiatives and healthcare reforms are playing a supportive role by subsidizing glucose monitoring devices, expanding reimbursement coverage, and launching public awareness campaigns. The growing emphasis on preventive healthcare and remote monitoring-accelerated by the pandemic-has placed wearable glucose monitors at the center of virtual care strategies. Partnerships between tech companies and healthcare providers are also creating more integrated ecosystems, combining wearables, EHRs, and AI analytics for comprehensive diabetes management. Consumer preference for minimally invasive and user-friendly devices is shaping R&D efforts, pushing manufacturers toward innovation in design and functionality. Furthermore, strategic expansion by key industry players into Asia-Pacific, Latin America, and the Middle East is opening new growth avenues. As technology matures and global health priorities shift toward proactive care, diabetes monitoring devices are set to become foundational tools in managing this pervasive disease.

SCOPE OF STUDY:

The report analyzes the Diabetes Monitoring Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices); Indication (Type-I Diabetes, Type-II Diabetes, Gestational Diabetes); End-User (Hospitals, Clinics, Home Care Settings, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â